Trius Confident After Phase II Results For Skin Infections, Including MRSA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Trius Therapeutics is headed into Phase III for its lead antibiotic candidate torezolid (TR-701) with an important advantage over other sponsors that have tried for a complicated skin and skin structure claim in the past year: Trius has a clear sense of the outcome FDA now expects to see in a noninferiority study.